Brief: Outlook Therapeutics® Announces Acceptance Of Biologics License Application By U.S. FDA
08/04/2025 14:27
April 8 (Reuters) - Outlook Therapeutics Inc OTLK.O: OUTLOOK THERAPEUTICS® ANNOUNCES ACCEPTANCE OF BIOLOGICS LICENSE APPLICATION BY U.S. FDA FOR ONS-5010 AS A TREATMENT FOR WET AMD OUTLOOK THERAPEUTICS INC - PRESCRIPTION DRUG USER FEE ACT (PDUFA) GOAL DATE OF AUGUST 27, 2025 Source text: ID:nGNXRkfL8 Further company coverage: OTLK.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Outlook Therapeutics
See all newsBrief: Outlook Therapeutics Appoints Kevin Lundquist As Chief Financial Officer As It Prepares For U.S. Commercial Launch Of Lytenava™
Outlook Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Outlook Therapeutics Q3 net loss narrows slightly as costs drop
U.S. STOCKS ON THE MOVE-Tapestry, Cisco, Sandisk
U.S. STOCKS ON THE MOVE-EnerSys, Netflix, Salesforce